UBS maintains Corpay at Neutral, raises price target to $465 from $415

UBS kept Corpay at Neutral but raised its price target to $465 from $415, a 12% increase. This implies a 4% upside from the Nov 5 close of $447. Recent analyst targets for Corpay range from $461 to $539.

Original reporting
Published Nov 6, 2026, 12:21 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 12:23 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
UBS maintains Corpay at Neutral, raises price target to $465 from $415 — source image
Decision brief

The 30-second read

Low
01

Why it matters

The target increase could attract modest buying interest but lacks a concrete catalyst.

02

Market read

Analyst price target revision with limited immediate market impact.

03

What to watch

No new earnings or guidance data accompany the target change.

Relevance 5/10Novelty 5/10Timing: today

Background

UBS analyst raised Corpay's price target from $415 to $465, implying modest upside.

Market effects

None

None

None

Counterpoint

The price target raise may be overly optimistic given limited new fundamentals.

Key entities

  • UBS

    Research firm issuing the price target update.

  • Corpay

    Payment platform subject of the price target change.

Related articles

$CPAYMedAI 8/10

Corpay 3Q 2026: Revenue $1.38B, EPS $5.66 — 10-Q Summary

Corpay reported 3Q 2026 revenue of $1.38B, up 17.9% YoY, and net income of $378.42M, up 36.2% YoY. Growth was driven by organic spend and transaction volumes, new sales, and acquisitions. Higher operating expenses and other costs partly offset gains. Management expects liquidity to meet needs for the next 12 months.

$CPAYHighAI 8/10

Corpay (CPAY) Q3 2026 Earnings Call Transcript

Corpay (CPAY) raised Q4 2026 revenue guidance to $1.37B and cash EPS to $7.65, up 27%. Full-year 2026 revenue is expected to rise 18%, with cash EPS up over 30%. For 2027, Corpay anticipates 9-11% organic revenue growth. The company has divested noncore businesses, using proceeds for share buybacks, and plans to allocate $2B in free cash flow to acquisitions or buybacks. Corporate Payments segment growth is expected to remain in the high teens.

$CPAYMed

Corpay Q3 Earnings Call Highlights

Corpay (NYSE:CPAY) expects 9-11% organic revenue growth in 2027, with $2B in free cash flow for acquisitions or share repurchases. The company divested noncore businesses in 2026, using proceeds for buybacks. Alpha and Avid are expected to contribute over $1.40 in combined cash EPS accretion in 2026. Corpay aims to compound adjusted EPS by over 20% annually through 2029.

$CPAYMed

Corpay Inc (CPAY) (Q3 2026) Earnings Call Highlights: Sixth Straight Quarter

Corpay Inc (CPAY) reported Q3 2026 earnings, guiding Q4 organic revenue growth at 10%, slightly below Q3's 11%. Corporate payments growth is ~17% excluding one-time items, while lodging and vehicle payments show mixed results. The company may pursue divestitures and is uncertain about acquiring the remaining stake in Avid. Operating costs rose 9%, and tax rate decreased to 23.4%. CEO Ronald Clarke highlighted strong corporate payments growth and potential for 2027.